Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | KLK7 | P49862 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24438513 | 0.85 | L3MBTL1 (0.44) | KMT2AL3MBTL1KLK7TRPM8KLK5 | |
| SCHEMBL20133087 | 0.79 | MEN1 (0.50) | MEN1KMT2AL3MBTL1BCHECREBBP | |
| SCHEMBL20128933 | 0.79 | MEN1 (0.50) | MEN1KMT2AL3MBTL1BCHECREBBP | |
| SCHEMBL21751819 | 0.79 | MEN1 (0.47) | MEN1KMT2AL3MBTL1BCHECREBBP | |
| SCHEMBL20128955 | 0.79 | MEN1 (0.50) | MEN1KMT2AL3MBTL1BCHECREBBP | |
| SCHEMBL21771133 | 0.79 | MEN1 (0.47) | MEN1KMT2AL3MBTL1BCHECREBBP | |
| SCHEMBL20120793 | 0.77 | MEN1 (0.46) | MEN1KMT2AL3MBTL1BCHECREBBP | |
| SCHEMBL20133212 | 0.77 | MEN1 (0.48) | MEN1KMT2AL3MBTL1BCHECREBBP | |
| SCHEMBL20120795 | 0.77 | MEN1 (0.46) | MEN1KMT2AL3MBTL1BCHECREBBP | |
| SCHEMBL20233781 | 0.76 | KDM4C (0.45) | MEN1KMT2AL3MBTL1BCHECREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | MEN1 1944/4885KMT2A 1250/4885L3MBTL1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.